Aggressive weight reduction treatment in the management of type 2 diabetes

Diabetes and Metabolism

Volumn 24, Issue 2, 1998, Pages 116-123

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anti obesity drugs; Gastroplasty; Obesity; Type 2 diabetes; Very low calorie diets

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; INSULIN; ORAL ANTIDIABETIC AGENT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

CLINICAL TRIAL; DIET THERAPY; GASTROPLASTY; HUMAN; INSULIN TREATMENT; LOW CALORY DIET; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL DRUG ADMINISTRATION; REVIEW; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; ENERGY INTAKE; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0031865956     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Scheen AJ, Lefèbvre PJ. Pathophysiology of Type 2 diabetes. In: Kuhlmann J, Puls W, eds. "Handbook of Experimental Pharmacology", Oral Antidiabetics. Berlin : Springer Verlag, 1995, 7-42.
2. Golay A, Felber JP. Evolution from obesity to diabetes. Diab Metab, 1994, 20, 3-14.
3. Pi-Sunyer FX. Weight and non-insulin-dependent diabetes mellitus. Am J Clin Nutr, 1996, 63 (Suppl), 426-429.
4. Scheen AJ, Lefèbvre PJ. Assessment of insulin resistance in vivo. Application to the study of type 2 diabetes. Horm Res, 1992, 38, 19-27.
5. Scheen AJ, Paquot N, Letiexhe M, Paolisso G, Castillo M, Lefèbvre PJ. Glucose metabolism in obese subjects : lessons from OGTT, IVGTT, and clamp studies. Int J Obesity, 1995, 19 (Suppl 3), S14-S20.
6. Walker M. Obesity, insulin resistance, and its link to non-insulin-dependent diabetes mellitus. Metabolism, 1995, 44 (Suppl 3), 18-20.
7. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther, 1996, 18, 1006-1035.
8. Brown SA, Upchurch S, Anding R, Winter M, Ramirez G. Promoting weight loss in type II diabetes. Diabetes Care, 1996, 19, 613-624.
9. Lefèbvre PJ, Scheen AJ. Management of non-insulin-dependent diabetes mellitus. Drugs, 1992, 44 (Suppl 3), 29-38.
10. Scheen AJ, Lefèbvre PJ. Managing the obese diabetic patient. In : Angel A, ed. "Progress in Obesity Research 94". London : J. Libbey. 1995, 93, 661-669.
11. Lefèbvre PJ, Scheen AJ. Improving the action of insulin. Clin Invest Med, 1995, 18, 340-347.
12. Scheen AJ, Desaive C, Lefèbvre PJ. Therapy for obesity - today and tomorrow. Baillière's Clin Endocrinol Metab, 1994, 8, 705-727.
13. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes in women. Ann Intern Med, 1995, 122, 481-486.
14. Long SD, O'Brien K, MacDonald KG et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal intervention study. Diabetes Care, 1993, 17, 372-375.
15. Pontiroli AE, Calderara A, Pacchioni M, Cassisa C, Pozza G. Weight loss reverses secondary failure of oral hypoglycaemic agents in obese non-insulin-dependent diabetic patients independently of the duration of the disease. Diab Metab, 1993, 19, 30-35.
16. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol, 1995, 141, 1128-1141.
17. Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Med, 1990, 7, 228-233.
18. Manning RM, Jung RT, Leese GP, Newton RW. The comparison of four weight reduction strategies aimed at overweight diabetic patients. Diabetic Med, 1995, 12, 409-415.
19. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 16 : Overview of 6 years' therapy of type II diabetes : a progressive disease. Diabetes, 1995, 44, 1249-1258.
20. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes. Diabetes Rev, 1995, 3, 308-334.
21. Jönsson B, Krans HMJ (Eds). The social and cost implications of type II diabetes. PharmacoEconomics, 1995, 8 (Suppl 1), 1-94.
22. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s : achievements and future developments. Drugs. 1997, 54, 355-368.
23. Bosello O, Armellini F, Zamboni M, Fitchet M. The benefits of modest weight loss in type II diabetes. Int J Obesity, 1997, 21 (Suppl 1), S10-S13.
24. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med, 1987, 147, 1749-1753.
25. Alberti KGMM, Gries FA, Jervell J, Krans HMJ for the European NIDDM Policy Group. A desktop guide for the management of non-insulin-dependent diabetes mellitus (NIDDM) : an update. Diabetic Med, 1994, 15, 899-909.
26. Amatruda JM, Richeson JF, Welle SL, Brodows RG, Lockwood DH. The safety and efficacy of a controlled low-energy (very-low-calorie) diet in the treatment of non-insulin-dependent diabetes and obesity. Arch Intern Med, 1988, 148, 873-877.
27. Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care, 1991, 14, 802-823.
28. Kelley DE, Wing R, Buonocore C et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1993, 77, 1287-1293.
29. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN. Caloric restriction per se is a significant factor in improvement in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care, 1994, 17, 30-36.
30. Bray GA, Ryan DH. Drugs used in the treatment of obesity. Diabetes Rev, 1997, 5, 83-103.
31. Carpenter MA, Bodansky HJ. Drug treatment of obesity in type II diabetes mellitus. Diabetic Med, 1990, 7, 99-104.
32. Scheen AJ, Lefèbvre PJ. Pharmacological treatment of the obese diabetic patient. Diab Metab, 1993, 19, 547-559.
33. Kosmiski L, Eckel RH. Anorectic agents in non-insulin-dependent diabetes mellitus. Curr Opin Endocrinol Diab, 1997, 4, 36-39.
34. Scheen AJ. Anti-obesity drugs in the treatment of NIDDM. Int Diabetes Monitor, 1997, 9, 1-8.
35. Willey KA, Molyneaux LM, Overland JE, Yue DK. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabetic Med, 1992, 9, 341-343.
36. Stewart GO, Stein GR, Davis TM, Findlates P. Dexfenfluramine in type II diabetes : effect on weight and diabetes control. Med J Aust, 1993, 158, 167-169.
37. Willey KA, Molyneaux LM, Yue DK. Obese patients with type 2 diabetes poorly controlled by insulin and metformin : effects of adjunctive dexfenfluramine therapy on glycaemic control. Diabetic Med, 1994, 11, 701-704.
38. Marks SS, Moore NR, Clark ML, Strauss BJG, Hockaday TDR. Reduction of visceral adipose tissue and improvement of metabolic indices : effect of dexfenfluramine in NIDDM. Obesity Res, 1996, 4, 1-7.
39. Chow C-C, Ko GTC, Tsang LWW, Yeung VTF, Chan JCN, Cockram CS. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. Diabetes Care, 1997, 20, 1122-1127.
40. Gray DS, Fujioka K, Devine W, Bray GA. Fluoxetine treatment in the obese diabetic. Int J Obesity, 1992, 16, 193-198.
41. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabetic Med, 1995, 12, 416-418.
42. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabetic Med, 1994, 11, 105-110.
43. Breum L, Bjerre U, Bak JF, Jacobsen S, Astrup A. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism, 1995, 44, 1570-1576.
44. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van Gaal L. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obesity Res, 1996, 4, 391-396.
45. Pestell RG, Crock PA, Ward GM, Alford FP, Best JD. Fenfluramine increases insulin action in patients with NIDDM. Diabetes Care, 1989, 12, 252-258.
46. Scheen AJ, Paolisso G, Salvatore T, Lefèbvre PJ. Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine. Diabetes Care, 1991, 14, 325-332.
47. Glaser B, Raveh Y, Norynberg C et al. Acute and chronic effects of dexfenfluramine on glucose and insulin response to intravenous glucose in diabetic and non-diabetic obese subjects. Diabetes Res, 1992, 19, 165-176.
48. Proietto J, Thorburn AW, Fabris S, Harrison LC. Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus. Diab Res Clin Pract, 1994, 23, 127-134.
49. Potter van Loon BJ, Radder JK, Frölich M, Krans HMJ, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese nondiabetic and obese non-insulin-dependent diabetic individuals. Int J Obesity, 1992, 16, 79-85.
50. Maheux P, Ducros F, Bourque J, Garon J, Chiasson J-L. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obesity, 1997, 21, 97-102.
51. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med, 1997, 337, 581-588.
52. Curfman GD. Diet pills Redux. N Engl J Med, 1997, 337, 629-630.
53. Lean MEJ. Sibutramine - a review of clinical efficacy. Int J Obesity, 1997, 21, S30-S36.
54. Shepherd G, Fitchet M, Kelly F. Sibutramine : a meta-analysis of the change in fasting plasma glucose in patients with a high baseline fasting value (≥ 5.5 mmol/l). Int J Obesity, 1997, 21 (Suppl 2), S54.
55. Leutenegger M, Hanotin C, Thomas F, Leutenegger E. Sibutramine in the treatment of obese patients presenting a risk of developing diabetes. Int J Obesity, 1997, 21 (Suppl 2), S55.
56. Guerciolini R. Mode of action of orlistat. Int J Obesity, 1997, 21 (Suppl 3), S12-23.
57. James WPT, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obesity, 1997, 21 (Suppl 3), S24-30.
58. Kelley D. A one-year study of weight loss and glycemic control in type II diabetics following orlistat (Xenical™) treatment. Obesity Res, 1997, 5 (Suppl 1), 21.
59. National Institutes of Health Consensus Development Conference Statement. Gastrointestinal surgery for severe obesity. Am J Clin Nutr, 1992, 55, 615S-619S.
60. Pories WJ, MacDonald KG, Flickinger EG et al. Is type II diabetes mellitus (NIDDM) a surgical disease ? Ann Surg, 1992, 215, 633-643.
61. Pories WJ, Swanson MS, MacDonald KG et al. Who would have thought it ? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg, 1995, 222, 339-352.
62. Sjöström CD, Lissner L, Sjöström L. Relationships between weight change, body composition and incidence of cardiovascular risk factors. Int J Obesity, 1996, 20 (Suppl 4), 95.
63. Herbst CA, Hughes TA, Gwynne JT, Buckwalter JA. Gastric bariatric operation in insulin-treated adults. Surgery, 1984, 95, 209-214.
64. Pories WJ, Caro JF, Flickinger EG et al. The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville gastric bypass. Ann Surg, 1987, 206, 316-323.
65. Pories WJ, MacDonald KG Jr, Morgan EJ et al. Surgical treatment of obesity and its effect on diabetes: 10-yr follow-up. Am J Clin Nutr, 1992, 55, 582S-585S.
66. Tourniaire J, Fimbel S, Penet D, et al. Traitement de l'obésité sévère par gastroplastie verticale calibrée. 55 observations. Presse Med, 1995, 24, 259-262.
67. Desaive C. A critical review of a personal series of 1000 gastroplasties. Int J Obesity, 1995, 19 (Suppl 3), S56-S60.
68. Letiexhe MR, Scheen AJ, Gérard PL, Desaive C, Lefèbvre PJ. Insulin secretion, clearance and action before and after gastroplasty in severely obese subjects. Int J Obesity, 1994, 18, 295-300.
69. Letiexhe MR, Scheen AJ, Gérard PL, Desaive C, Lefèbvre PJ. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab, 1995, 80, 364-369.
70. Scheen AJ, Luyckx FH, Triches K, Letiexhe MR, Desaive C, Lefèbvre PJ. Anomalies de la tolérance au glucose dans l'obésité sévère : réversibilité après amaigrissement induit par une gastroplastie. Rev Fr Endocrinol Clin, 1997, 38, 217-224.